PGEN Positive Sentiment
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Thursday, March 13, 2025 BiopharmaWatch Research 1 min read Key Takeaway: Precigen, Inc. has announced that it will release its full-year 2024 financial results and provide business updates on March 19, 2025. A conference call will be held at 4:30 PM ET to discuss these results. Participants are encouraged to join the call early to ensure timely connection. Precigen focuses on developing advanced gene and cell therapies.
Full Press Release Details
GERMANTOWN, Md.,March 13, 2025/PRNewswire/ --Precigen, Inc.(Nasdaq:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates onWednesday, March 19, 2025. The Company will host a conference call to discuss results that day at4:30 PM ET.
The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Event details can be found on Precigen's website in the Events & Presentations section atinvestors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®Precigen (Nasdaq:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visitwww.precigen.comor follow us onLinkedInorYouTube.
Cautionary Statement Regarding Forward-Looking StatementsSome of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:Steven M. HarasymTel: +1 (301) 556-9850[email protected]
Media Contacts:Donelle M. Gregory[email protected]